Emerging strategies in renal cell carcinoma are focusing on new drugs and personalized approaches to improve patient outcomes.
Next-generation kinase inhibitors like Zanzalintinib show promise with high disease control rates in early trials. The Phase 3 STELLAR-304 study is testing it with Nivolumab as frontline therapy for non-clear cell RCC.
Hypoxia-inducible factor (HIF)-2α inhibitors are emerging as strong second-line options. In the LITESPARK-011 trial, Belzutifan combined with Lenvatinib significantly improved progression-free survival compared to cabozantinib. Another inhibitor, casdatifan, is entering Phase 3 trials to confirm similar benefits.
Researchers are also exploring the gut microbiome and surgical timing to boost immunotherapy. Adding the live biotherapeutic CBM588 to immunotherapy extended progression-free survival in a small study. Trials like PROBE are evaluating whether delaying surgery can enhance immune responses.
Overall, the RCC field is moving toward triplet combinations and biology-driven, personalized treatment strategies to maximize effectiveness and patient benefit.